The Goldman Sachs Group Upgrades Bruker (NASDAQ:BRKR) to “Strong-Buy”

Bruker (NASDAQ:BRKR) was upgraded by research analysts at The Goldman Sachs Group from a “strong sell” rating to a “strong-buy” rating in a report issued on Monday, Zacks reports.

A number of other brokerages have also recently issued reports on BRKR. Leerink Partners upped their price objective on shares of Bruker from $60.00 to $70.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Wolfe Research initiated coverage on shares of Bruker in a report on Monday, June 1st. They issued a “peer perform” rating on the stock. Barclays lifted their price objective on Bruker from $53.00 to $60.00 and gave the company an “overweight” rating in a research report on Wednesday, June 24th. Weiss Ratings restated a “sell (d+)” rating on shares of Bruker in a report on Monday, August 31st. Finally, Stifel Nicolaus set a $50.00 price target on Bruker in a research report on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Bruker presently has an average rating of “Moderate Buy” and a consensus target price of $57.00.

Bruker Stock Down 2.5%

BRKR opened at $59.67 on Monday. The company’s 50-day moving average price is $58.27 and its two-hundred day moving average price is $50.44. Bruker has a twelve month low of $30.09 and a twelve month high of $65.30. The stock has a market cap of $9.09 billion, a price-to-earnings ratio of -85.24, a PEG ratio of 1.87 and a beta of 1.26. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76.

Bruker (NASDAQ:BRKR) last issued its earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.11. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The business had revenue of $838.50 million for the quarter, compared to analysts’ expectations of $853.57 million. During the same quarter in the previous year, the firm posted $0.32 EPS. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities analysts expect that Bruker will post 2.12 earnings per share for the current year.

Insider Activity

In related news, VP Mark Munch sold 2,000 shares of the stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $52.87, for a total transaction of $105,740.00. Following the completion of the transaction, the vice president directly owned 134,806 shares of the company’s stock, valued at approximately $7,127,193.22. This represents a 1.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 27.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of BRKR. Pallas Capital Advisors LLC bought a new stake in shares of Bruker in the second quarter valued at about $570,746,000. Sculptor Capital LP increased its position in Bruker by 9.0% during the 1st quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company’s stock valued at $118,112,000 after buying an additional 270,000 shares in the last quarter. Edmond DE Rothschild Holding S.A. purchased a new position in shares of Bruker in the 2nd quarter valued at approximately $169,899,000. Dimensional Fund Advisors LP lifted its stake in shares of Bruker by 23.7% during the first quarter. Dimensional Fund Advisors LP now owns 2,341,518 shares of the medical research company’s stock worth $84,556,000 after buying an additional 448,440 shares during the period. Finally, Franklin Resources Inc. raised its stake in shares of Bruker by 317.7% in the fourth quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock worth $108,796,000 after purchasing an additional 1,756,460 shares during the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and software used to study the chemical, physical and biological properties of materials. Its customers include universities, pharmaceutical and biotechnology companies, industrial manufacturers, hospitals, government laboratories and other research organizations.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray analysis instruments, optical and molecular spectroscopy systems, microscopy and nanoanalysis tools, and instruments for microbiology and spatial biology.